Patents Assigned to Merck
  • METHOD FOR PRODUCING SILICA PARTICLES, SILICA PARTICLES PRODUCED BY SUCH METHOD, COMPOSITIONS AND USES OF SUCH SILICA PARTICLES
    Publication number: 20240351889
    Abstract: The present application relates to a method for producing silica particles, and to the silica particles produced by such method. The present application further relates to compositions comprising the silica particles produced by such method as well as to uses of such silica particles and compositions comprising such silica particles.
    Type: Application
    Filed: August 10, 2022
    Publication date: October 24, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Eric JACQUINOT, Leo HANUS, Geary GRAHAM
  • SYRINGES AND INJECTORS WITH CAPACITIVE SENSING LOCKS AND METHODS OF MAKING AND USING SAME
    Publication number: 20240350738
    Abstract: An injecting device comprises a reservoir for containing a medicament, a needle in communication with the reservoir and configured to deliver the medicament to a patient's body, a capacitance sensor disposed adjacent to the needle, and a plunger rod assembly comprising a housing and a piston, the housing and piston being configured to transition between a locked condition in which the piston and the housing are coupled to move together, and an unlocked condition in which the piston is capable of translating relative to the housing.
    Type: Application
    Filed: September 7, 2022
    Publication date: October 24, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John B. Cline, Jeffrey C. Givand, Guangli Hu, Edward Yeung
  • Anti-PD-1 antibodies
    Patent number: 12122834
    Abstract: The present invention relates to anti-PD-1 antibodies and antigen-binding fragments, and use of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 22, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Laurence Fayadat-Dilman, Veronica Juan, Shireen Khan, Shaopeng Huang, Hua Ying
  • Stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
    Patent number: 12122783
    Abstract: The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: October 22, 2024
    Assignee: MERCK & CIE
    Inventors: Rudolf Moser, Viola Groehn, Thomas Egger, Thomas Ammann
  • Negative resist formulation for producing undercut pattern profiles
    Patent number: 12124166
    Abstract: A negative-acting, photoresist composition, imageable by 365 nm radiation that is developable in aqueous base. Apart from solvent, this composition comprises: a) an aqueous base soluble phenolic film-forming polymeric binder resin having ring bonded hydroxyl groups; b) a photoacid generator c) a crosslinking agent which comprises an etherified melamine; d) a dye as described herein; e) a quencher system consisting essentially of an amine quencher, or a mixture of such amine quenchers, as described. This invention also pertains to processes of using this composition as a photoresist.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 22, 2024
    Assignee: Merck Patent GmbH
    Inventors: Anupama Mukherjee, Medhat A. Toukhy
  • METHODS FOR MAKING POLYSACCHARIDE-PROTEIN CONJUGATES
    Publication number: 20240342263
    Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.
    Type: Application
    Filed: June 28, 2024
    Publication date: October 17, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jitin Bajaj, Michael Albert Winters, Emily Wen, Jian He
  • METHOD FOR ANALYZING TRACE LEVELS OF SEMI-VOLATILE NITROSAMINES IN SOLID SAMPLES
    Publication number: 20240345038
    Abstract: This invention describes a novel method encompassing preparing a nitrosamine sample. adding in relevant chemicals that reduces or eliminates in situ nitrosamine formation, utilizing full evaporation static headspace gas chromatograph coupled with nitrogen phosphorous detector (FE-SHSGC-NPD), and analysis of rapid results in the gaseous phase for sensitive detection of semi-volatile nitrosamines, including ND.MA.
    Type: Application
    Filed: July 11, 2022
    Publication date: October 17, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Rebecca Evans, Xinxin Han, Daniel E. Lee, Christine L. Radich, Jinjian Zheng
  • Smart consumables/identifier label and antenna for smart consumables/identifier label
    Patent number: 12118420
    Abstract: Described herein is a label 1 for marking containers or equipment by adhering the label to a surface thereof. The label 1 includes a support material base 11, at least one RFID microelectronic device 5c included in the support material base 11, and a plurality of antennas 5a,5b for different frequency ranges connected with the at least one RFID microelectronic device 5c and included in the support material base 11. The plurality of antennas 5a, 5b include a first antenna 5a for the frequency range of 860 to 960 MHz and having a theoretical read range peak of more than 4 m when provided on a glass surface, and the label has a dimension of 40 mm*20 mm or less.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: October 15, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Christian-Hubertus Kuechenthal, Roja Azees, Dan Kvelstad, Sven Erfurth
  • Liquid crystal medium
    Patent number: 12116521
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising a compound of formula I and one or more compounds of formula II as defined in claim 1, and to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays, especially in IPS, FFS, VA or PS-VA displays.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: October 15, 2024
    Assignee: MERCK PATENT GMBH
    Inventor: Sven Christian Laut
  • STREPTOCOCCUS PNEUMONIAE SEROTYPE-SPECIFIC DETECTION ASSAY, REAGENTS AND KITS
    Publication number: 20240337656
    Abstract: S. pneumoniae is a major cause of community-acquired pneumonia (CAP) in young children, older adults, and those with conditions or medications that compromise their immunity. Since the introduction of pneumococcal vaccines, the disease burden of vaccine serotypes (STs) on invasive pneumococcal disease has reduced; however, the effect on the burden of CAP is less well known, potentially due to a lack of testing for pneumococcal STs.
    Type: Application
    Filed: April 3, 2024
    Publication date: October 10, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Zhifeng Chen, Kara S. Cox, Katrina M. Nolan, Gowrisankar Rajam, Jeanette F. E. Roman, Mary Lillian Shank-Retzlaff, Thorsten Verch, Kalpit A. Vora
  • IL4I1 INHIBITORS AND METHODS OF USE
    Publication number: 20240336608
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, A, and B are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.
    Type: Application
    Filed: March 27, 2024
    Publication date: October 10, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: David A. Candito, Anthony Donofrio, Ronald Dale Ferguson, II, George Madalin Giambasu, Anmol Gulati, Andrew M. Haidle, Brett A. Hopkins, William P. Kaplan, Ping Liu, Michaelyn C. Lux, Xiao Mei Zheng, Ryan D. Otte, Alexander Pasternak, Elsie C. Yu
  • SOLID-PHASE GLYCAN REMODELING OF GLYCOPROTEINS
    Publication number: 20240336946
    Abstract: A solid-phase glycan remodeling (SPGR) system for the glycoengineering of glycoproteins to provide glycoprotein compositions comprising particular predominant glycoforms is described.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 10, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: YEN-PANG HSU, BENJAMIN F. MANN, SHUWEN SUN, DEEPTAK VERMA
  • NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20240335529
    Abstract: A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections.
    Type: Application
    Filed: June 20, 2024
    Publication date: October 10, 2024
    Applicant: Merck Patent GmbH
    Inventors: Ursula Boschert, Urs Wiedemann
  • Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof
    Patent number: 12110330
    Abstract: The invention provides compositions of anti-PD-1 antibodies or antigen-binding fragments thereof with less than or equal to about 3.0% oxidation of Met105 in the CDRH3 heavy chain region, and methods of obtaining the purified compositions. The invention also provides compositions comprising anti-PD-1 antibody main species and acidic species thereof, wherein the amount of acidic species is about 1.0-12.0%.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: October 8, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Mark A. Brower, Chung-Jr Huang, Brian Wai Kwan, William Nicholas Napoli, Bhumit A. Patel, Nuno J. Dos Santos Pinto, Douglas Dennis Richardson, II, Sen Xu
  • DOSAGE REGIMEN FOR ADMINISTRATION OF BELZUTIFAN
    Publication number: 20240327929
    Abstract: The present disclosure provides a method of treating cancer or von Hippel-Lindau (VHL) disease with a safe and effective therapeutic dose of belzutifan in a patient in need thereof, comprising: (i) determining the belzutifan metabolic status (BMS) of the patient to determine whether the patient has a low metabolizer status, medium metabolizer status, or fast metabolizer status and (ii) (a) if the patient has the medium or fast metabolizer status, administering belzutifan to the patient at a standard therapeutic dose of 120 mg: or (ii) (b) if the patient has the low metabolizer status, administering belzutifan, to the patient at a therapeutic dose below that of the standard therapeutic dosc.
    Type: Application
    Filed: August 8, 2022
    Publication date: October 3, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Thomas J. BATEMAN, Aparna CHHIBBER, Eunkyung KAUH, Dhananjay Devidas MARATHE, Peter M. SHAW, Rachel MARCEAU WEST
  • ORGANOID MICROINJECTION SYSTEM AND APPARATUS
    Publication number: 20240327773
    Abstract: A microinjection system and apparatus comprising stationary trough chips having wells and troughs to allow for efficient organoid microinjections are described.
    Type: Application
    Filed: September 7, 2022
    Publication date: October 3, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jason A. Cassaday, Erik C. Hett, Stephen H. Kasper, Linda Adelle Lieberman, Sina Mohammadi, Carolina D. Morell-Perez, Clifford Sampson, Brian Andrews Squadroni
  • PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20240327391
    Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
    Type: Application
    Filed: May 23, 2024
    Publication date: October 3, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Yeon-Hee Lim, Jianming Bao, James P. Roane
  • ANTIBODIES THAT BIND METAPNEUMOVIRUS, ANTIGENIC METAPNEUMOVIRUS PROTEINS, AND USES THEREOF
    Publication number: 20240327502
    Abstract: The present invention relates to anti-human metapneumovirus (hMPV) antibodies, as well as use of such antibodies in the treatment of viral infections. The invention also includes antigenic hMPV proteins and immunogenic compositions comprising such antigenic hMPV proteins, and the use of such antigenic hMPV proteins and related compositions for preventing or treating viral infection in a subject.
    Type: Application
    Filed: February 8, 2022
    Publication date: October 3, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Zhifeng CHEN, Kara S. COX, Arthur FRIDMAN, Jennifer Dawn GALLI, Hua-Poo SU, Aimin TANG, Kalpit VORA, Zhiyun WEN, Xiao XIAO, Lan ZHANG
  • Materials for organic electroluminescent devices
    Patent number: 12108665
    Abstract: The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: October 1, 2024
    Assignee: Merck KGaA
    Inventors: Amir Parham, Philipp Stoessel, Christian Ehrenreich
  • Anti-LAG3 antibodies and antigen-binding fragments
    Patent number: 12102681
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: October 1, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan